A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.

Author: AgrawalSanjay, BirringSurinder S, MaherToby M, MoriceAlyn H, StoneHelen, TutuncuAhmet, WijsenbeekMarlies S, van den BergJan W K

Paper Details 
Original Abstract of the Article :
Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/S2213-2600(17)30310-7

データ提供:米国国立医学図書館(NLM)

Inhaled Sodium Cromoglicate: A New Oasis for Persistent Cough

The [idiopathic pulmonary fibrosis (IPF)] landscape is often a dry and barren desert, with [persistent cough] adding to the discomfort. This study explores the potential of a novel formulation of [inhaled sodium cromoglicate (PA101)] as a treatment for cough associated with IPF. The researchers conducted a double-blind trial, comparing the effects of PA101 with a placebo group in patients with chronic idiopathic cough (CIC). Their findings offer valuable insights into the potential of PA101 as a safe and effective antitussive therapy, potentially providing relief for patients struggling with persistent cough.

PA101: A New Hope for Cough Relief in the Desert of IPF

This study, like a camel caravan discovering a new water source, reveals the potential of PA101 as a promising treatment for persistent cough. The researchers found that PA101 was well-tolerated and showed a significant reduction in cough frequency compared to placebo in both IPF and CIC patients. This discovery offers a glimmer of hope for patients seeking relief from this debilitating symptom.

Navigating the Desert of Cough: Finding Relief and Improving Quality of Life

Persistent cough can significantly impact quality of life. This research, like a map guiding us towards a calmer oasis, provides valuable insights into potential treatment options. While further research is needed to confirm PA101's long-term effectiveness, the study's findings offer a promising avenue for relief for patients struggling with persistent cough associated with IPF.

Dr. Camel's Conclusion

This study, like a camel caravan seeking a respite from the harsh desert conditions, highlights the potential of PA101 as a treatment for persistent cough. The findings offer hope for patients seeking relief from this debilitating symptom, potentially improving their quality of life. Remember, friends, navigating the desert of chronic illness requires a relentless pursuit of solutions, a commitment to improving well-being, and a belief in the power of innovation.

Date :
  1. Date Completed 2018-06-05
  2. Date Revised 2018-06-05
Further Info :

Pubmed ID

28923239

DOI: Digital Object Identifier

10.1016/S2213-2600(17)30310-7

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.